Radiopharmaceuticals for Breast Cancer

Nuclear medicine physician Dr. Munir Ghesani is studying how radiopharmaceuticals — drugs that contain a small amount of radioactive material — can be used to treat metastatic HER2-negative and triple-negative breast cancer. While the studies are very early, he’s very hopeful about the results.
Listen to the episode to hear Dr. Ghesani explain:
- Sponsor Message
how radiopharmaceuticals work
- Sponsor Message
the side effects radiopharmaceuticals can cause
- Sponsor Message
how doctors decide which radioactive substance is best for treating specific cancers
Welcome to The Breastcancer.org Podcast, the podcast that brings you the latest information on breast cancer research, treatments, side effects, and survivorship issues through expert interviews, as well as personal stories from people affected by breast cancer. Here's your host, Breastcancer.org senior science reporter, Jamie DePolo.
Jamie DePolo: Hello. Thanks for listening. You've probably seen or heard ads for medicines like Pluvicto to treat prostate cancer. Pluvicto is what's called a radiopharmaceutical, a drug that contains a small amount of a radioactive substance. The healthcare specialty that focuses on using radiopharmaceuticals is called nuclear medicine. Currently, there aren't any radiopharmaceuticals approved to treat breast cancer, but research studies are ongoing.
I'm joined by Dr. Munir Ghesani, a nuclear medicine physician and chief medical officer of United Theranostics. He's going to explain in more detail how radiopharmaceuticals work, as well as talk about some of the studies he's overseeing using radiopharmaceuticals to treat breast cancer. Dr. Ghesani, welcome to the podcast.
Dr. Munir Ghesani: Thank you, Jamie. I appreciate the invitation to join the podcast.
Jamie DePolo: Excellent. So, I briefly explained what radiopharmaceuticals are in the introduction. Could you give us a little more background? How did they come to be developed, and how exactly do they work?
Dr. Munir Ghesani: Sure. So interestingly, the roots of radiopharmaceutical, at its most basic level, they go back 85 years when in Boston, back in 1941, when a radioactive iodine was given for thyroid disease. And it was something that really transformed the field of nuclear medicine, or now we call it also nuclear oncology, in a way that is very different than most other forms of cancer therapeutics.
So let me give you the examples of a few treatments that the audience may be very familiar with. For example, chemotherapy or immunotherapy, which are very commonly given for patients with breast cancers. And those treatments, once you administer, you have no control over where they go, or you have no control over how to find where they're going.
As opposed to that, the radiopharmaceuticals are very different. We can see what we treat and treat what we see. What I mean by that is the audience may have heard, while as you just mentioned, the breast cancer is not where the radiopharmaceutical therapies are given.
But clearly, there are PET scans that are very valuable in patients with breast cancer. So some of the members of the audience may have personally gone through a PET scan, or they may know somebody who may have PET scans, and what they do is they find, with very high degree of reliability, all the areas in the body that the cancer might be there.
What has been progressed from that point onwards is that same technology that finds the cancer can also, by simply switching the nuclear medicine isotope that we use, can convert that from what can give you the information about where this cancer is, to where it can then treat without changing any fundamental structure of that molecule. So in other words, it's a one-on-one relationship. What we see is what we are going to treat, but then it takes a step further.
Once we administer the treatment, unlike chemotherapy or immunotherapy, where you have no control over where you're going or where you can see it, radiopharmaceutical therapy can give you precise information of where the treatment was actually delivered. So this way, we first confirm that all the cancer cells are taking up our treatment by seeing what we are going to treat, but once we administer that treatment, then we go back and image what we just treated.
This is something that is very unique to radiopharmaceutical therapy, and as we will discuss further in the breast cancer space, multiple treatment options are being explored. So it's only going to be a matter of time before these treatments will become available for patients with breast cancer.
Jamie DePolo: Thank you for that. Now, you mentioned PET scans, and I'm wondering what is the difference between the radioactive tracer that is used in a PET scan and the radioactive tracer that might be used to treat a cancer? Is it the level of radioactivity, or? Help me understand that, please?
Dr. Munir Ghesani: That's a very important question, and that's… the audience needs to understand the difference. So you know, I'll give you a little metaphor for this, which is that if you think about you're trying to cross the enemy line. And you need to send your frontline soldiers to find out where the enemy is situated, and you need to get that information back to the central command. That analogy would be the analogy of the PET scan.
So the PET scan gives you the details of where the bad actors in the body are. That molecule is the one that gave you that information. So you do not want to change that molecule. But then what you do is you switch the radioisotope [so] that instead of giving you a homing signal, it provides you the necessary weaponry that kills where the signal came from.
So the isotope that's used for radiopharmaceutical therapy is typically what's called particle. They don't travel too far, but once they find their target, they just deposit all their energy where the target occurred. Whereas PET scans travel far, but they provide the necessary information before you act on killing those cancer cells.
Jamie DePolo: Okay. Okay. Thank you for explaining that. I believe I understand.
So I know for PET scans, and I don't mean to keep harping on this, but I want to make sure I understand, you can have different tracers, depending on, I think, which organ or which area of the body is being imaged or what type of cancer it is. Are there different radioactive substances that are used, you know, radiopharmaceutical to treat cancer, or is it basically the same one every time?
Dr. Munir Ghesani: That's a great question, and what is very interesting, we are very grateful for our very smart radiochemists who come up with all the options. Essentially, what I tell people is that no option on the periodic table is left behind. And when it comes to that, taking full advantage of the periodic table, you can essentially divide that into two parts. Once, as you mentioned, the PET scan, but even the isotopes that give you the PET scan signal have different characteristics. So for example, you can use fluorine-18 or you can use gallium-68 or copper-64.
These are all homing devices, but they have different strengths. One of them may give you more precise localization to where exactly the cancer is. The other one have little longer half-life, meaning that from the moment you order it from the radiopharmacy, until the moment it comes to you, if it only lasts for an hour, and if it took an hour in transit, then by the time it comes to you, it has no longer any strength remaining.
Whereas there are others who have the half-life of 13, 14 hours. And those give you flexibility of — you can order, and if it takes you two or three hours for it to be delivered, you're still okay because you can use that signal without losing the potency. So that's the analogy of the PET scan, and when it comes to the treatment, there are different kinds of energy the treatment can deliver. Some of them work on very big tumors so that they can travel a little distance and create a crossfire effect so that the cancer is large. They can still cover the whole cancer.
Whereas there are some breast cancers that spread to a small area in the body or that you need a different type of radioisotope that precisely deposits its energy exactly where it originated. So that's what I mean by having a huge advantage of the radiochemists who are leaving no option behind.
Jamie DePolo: Okay, and then, I am curious, before we get into some specifics about the studies that you're overseeing, what about side effects? Are there general side effects that are common to all types of radiopharmaceuticals? And also, are there certain, say, radioactive substances — you were just talking about how you can use the whole periodic table — do certain radioactive substances cause different side effects?
Dr. Munir Ghesani: That's a great question. So there's one thing which is common in all radiopharmaceuticals, is that compared to chemotherapy or immunotherapy, their deposition preferentially to the cancer cells is much more potent. What that means is that they spend most of their energy in targeting the cancer cells, which also means that the normal body tissues get less effect of that treatment.
So there are a number of studies, now, over the last 10 to 12 years that have shown, time and again, that compared to chemotherapy or radiation therapy, that the radiopharmaceuticals, in general, cause much less side effects. In fact, in some of these trials, the investigators have gone back and said, well, we did notice that patients live longer. We also noticed that the patients’ cancer came back much later compared to chemotherapy or immunotherapy.
But we actually went back and asked the patient specific questions of, how did you tolerate this compared to your chemotherapy or immunotherapy? And inevitably, these treatments were much better tolerated. So across the board, it has been proven, time and again, that radiopharmaceutical therapies are much better tolerated.
Now, they're not absolutely without the side effects, and you asked the question, are there some things that are common, and are there any differences? So, yes, both of them. There are a few things that are in common.
Because the radiation is killing the cancer, the cancer cells are now disturbed, and they start to create some release of the hormones, what we call cytokines, and that makes people feel tired. So what we find, in general, is that for the first few days after treatment, the patients feel a little fatigued and weak, but then, suddenly, once that hump is over, the patients feel a whole lot more energy, and they feel much better than they ever felt before they started with treatment. So this is a biphasic reaction that occurs. First, they feel fatigued and weak. But then once they are overcoming that first three to four days of weakness and fatigue, they feel much better.
The other thing we need to watch out for is that depending on where else in the body these radiopharmaceuticals go, they may create some side effects, and that's where preventive measures come in very, very effectively. So, what we do at United Theranostics is that we don't just treat the patients. We also know, very well, what are the known side effects and how to prevent them.
So for example, if the treatment is getting cleared by the kidneys, we proactively tell the patients to come in well-hydrated, but on top of it, we also give them the hydration through IV, and that improves the clearance by the kidneys so that the side effects to the kidneys are considerably decreased.
There are some other treatments that get excreted by the salivary glands, and in addition to the hydration that helps the clearance from salivary glands, we give them instructions on taking simple measures, but they go a long way. For example, lemon wedges or sour candies that improve the clearance from the salivary gland. So these patients feel less side effects of the radiation. So while some side effects are commonly seen, like for the kidneys or salivary glands or bone marrow, I think we have a lot of opportunities to do proactive measures to minimize those side effects.
Jamie DePolo: Okay. Okay. That's very interesting. And now I do want to ask you about the early studies that United Theranostics has that you're overseeing specifically focused on breast cancer. So if we could talk a little bit about that, and then, I'm also curious, you know, I know Pluvicto is on the market for prostate cancer. So I'm curious, I know we have these early studies in breast cancer. Was there something unique about prostate cancer that made that treatment come to market first, or was it just that the research was further?
Dr. Munir Ghesani: Yeah, I can explain all of that. So every cancer in the body has a potential target for the radiopharmaceuticals to be able to work on them. It is just that when the patients were being explored for various treatments, the antigen on the prostate cancer cells has been explored for several decades.
In fact, its roots were when the monoclonal antibodies were first investigated in 1971, and then, people started to look at, is there any opportunity for prostate cancers to treat with monoclonal antibodies? And first, the scans started to come in for imaging prostate cancers, and they were successful to a certain extent.
But once we found out that cancer cells can be targeted on their cell surface using this kind of approach, people thought, well, if you can be targeting for scanning them, potentially we can also treat them. And so, that occurred over time, where what we call what we see, what we treat and what we treat, what we see, that concept was established much earlier in prostate cancer compared to breast cancer.
But that does not mean that we are too far behind in having our breast cancer patients benefit from this revolutionary technique. So at the moment, once we found out that the concept of nuclear medicine works for both scanning and treatment, now there are multiple clinical trials undergoing for various types of breast cancer as well.
Jamie DePolo: Okay, and what are some of the United Theranostics? What specifically are your studies looking at?
Dr. Munir Ghesani: Yeah. So that's a good question. The audience, I have noticed, overall, that breast cancer patients are very well educated. They research quite a bit, and when they come to us, they are very informed about the types of the cancer, and that credit goes to several sources, including sources like yours, who are constantly out there improving the awareness, spreading the knowledge, but also, in general, the breast cancer patients, I find that they are extremely proactive, and they would understand that not all breast cancers are the same.
There are estrogen receptors, there are progesterone receptors, there are HER2 receptors, there are subtypes, such as lobular carcinoma. They're all very different. So when it comes to treating the breast cancer with radiopharmaceutical therapy, the researchers are taking full advantage of knowing the Human Genome Project and its benefits that we have right now, where you have multiple different ways to subtype breast cancer.
And so, when we offer these clinical trials, we offer customized for that individual patient. We don't say we have a treatment for breast cancer. What we say is we have a treatment for estrogen receptor- and progesterone receptor-positive and HER2-negative breast cancer. Or we have treatments for what's called triple-negative breast cancer, meaning they have none of those present. They don't have estrogen receptors, they don't have progesterone receptors, they don't have HER2-neu receptors, and that's a very different type of cancer than estrogen and progesterone receptor-positive cancer. So all the researches that are going on, are going on specifically for very personalized, customized treatment for that given patient, rather than putting all breast cancer patients in a single bucket.
Jamie DePolo: Sure, that makes very good sense. And so, are those two subtypes, the hormone receptor-positive, HER2-negative and triple-negative, are those two subtypes what you are studying radiopharmaceuticals for?
Dr. Munir Ghesani: Yes. That's correct. Yeah.
Jamie DePolo: Yes. Okay. Okay, perfect. And I'm curious, is that for metastatic disease or is that for an earlier stage?
Dr. Munir Ghesani: So currently, it is at a metastatic disease setting, and when all the other treatments have failed is when we come in. But that's usually the norm for all of these trials, is that, you know, they usually find when all the other options are no longer there is when these treatments are being explored. But once you find the proof of concept, then what we realize is that sooner in the journey of the people you treat, more powerful the effects are, which is why we always encourage that.
For example, take a prostate cancer journey. You gave that example earlier why the prostate cancer treatment was attempted first, and I explained the reason. But there's also one thing more that we need to learn from prostate cancer journey is that the very first approval of prostate cancer treatment occurred when the patients had far progressed in their journey, had multiple hormone therapies, had at least one chemotherapy cycle is when the radiopharmaceutical was first explored.
And just about a month ago, this is very coincidental to this podcast, is just about a month ago, FDA looked at the data and realized that, in fact, if you treat the prostate cancer with radiopharmaceuticals up front, it makes even more of a difference in the outcome of these patients.
So just about a month ago, we started treating prostate cancer patients in much earlier stage of their journey. I have no doubt that once we establish a proof of concept in more advanced stage of breast cancer, that we will ultimately find that it may have even more value in the earlier stage of their disease.
Jamie DePolo: That makes sense because other researchers have told me that that's usually where the research starts, is in metastatic, because that's where, essentially, it's needed most because these are people who may not have a lot of treatment options. And then, when that's successful, it just keeps moving forward to see if it can make a difference earlier and earlier. So, it sounds like that's what you're saying.
Dr. Munir Ghesani: Yeah. You’re absolutely correct. Yeah. Yeah.
Jamie DePolo: Yeah. Okay. Okay. Now, if someone were participating in one of your studies, do they have to take any special precautions? I guess, ultimately, I'm wondering if someone would be radioactive for a certain amount of time after receiving one of these treatments.
Dr. Munir Ghesani: Yeah. So great question. In fact, what I generally do is that in my very first encounter consultation with the patient, I usually block out 90 minutes of my time because, you know, the patients are increasingly noticing that physicians don't have time to interact with them, and that creates a lot of anxiety because they walk away from the initial consultations having concerns that not all of their questions were answered or they were not able to allocate enough time to discuss all the treatment details.
So what we do is that we do two things. One, I block out 90 minutes of my time for the consultation, because that's my first encounter with the patient. But I also insist that they bring their family members because, you know, patients may be distracted, they may be a little depressed, and they may not have full strength and mental capacity to grasp all the discussions that take place.
So the family members come in. Generally I find that it's a family member who brings a notebook and writes the details, but then, on top of it, we give them printed instructions that are customized for that patient. And because the radiation is beneficial to them, but you need to minimize the radiation to others, that includes the family members, the colleagues at work, children, you know, social contacts. So there is a concept called ALARA, which is as low as reasonably achievable, and that concept is applied in every single encounter.
So what we give them instructions is that for the first three to four days, they need to sleep alone. They need to keep the contacts to more than three feet from each other and avoid contact with the children and pregnant women for about seven days. So all those instructions are very critical in making sure that patients get the maximum benefit, but the others do not get unnecessary radiation exposure.
Jamie DePolo: Okay, that makes sense. I don't mean to harp on this either, but I'm wondering if somebody, say, couldn't care for themselves, is it possible that they could be in a care facility or a hospital for the week or so after the treatment just to get some help that way?
Dr. Munir Ghesani: So typically, what we do is that situation comes in once in a while, and what we do is we do a separate consultation with a caregiver, and the reason is that the patients, after receiving these treatment, should not be going to the hospital or checking in a hotel because, you know, these facilities are not equipped, especially the hotels.
They are not equipped to handle the radioactivity. And so, which is where more controlled environment with particular training of the, either family members, and to your point, if the family is not able to take care of them, then it's usually the nurses or the aides who we usually discuss the details of what the radiation precautions are.
For example, making sure they don't get contamination, they use the gloves, they flush the toilet twice, they wipe down the toilet seats, and avoid sharing the food and other things to reduce that likelihood of cross-contamination. But in general, we do one-on-one training with caretakers rather than sending the patients to the hospital or to the hotel.
Jamie DePolo: Okay, that makes sense. Thank you for that. That's helpful. And then, finally, how do you see the timeline of radiopharmaceuticals to treat breast cancer moving? Do you think we might have an approved medicine in the next five or 10 years? Would it be longer? And I'm assuming it would be for one of the subtypes that you mentioned, probably hormone receptor-positive, HER2-negative, or triple-negative.
Dr. Munir Ghesani: That's a great question. First, I thought that you're going to ask me if these treatments will be available in six months or a year. I started getting concerned that…
Jamie DePolo: Yeah. No. No. No.
Dr. Munir Ghesani: But you're very practical, and in fact, if the trials go well, I'm a little more optimistic. I don't think that it will take 10 years.
Jamie DePolo: Oh, really? Okay.
Dr. Munir Ghesani: I think if the trials are run properly, and there are a few things, right? You need to have at least three things you need to make sure that happens.
The regulatory authorities want to make sure the first and foremost is, first, do no harm. So if these treatments are very toxic and cause many side effects, then, obviously, they should not be approved. Fortunately, we don't find that's the case with the radiopharmaceuticals. So, that's one reassurance.
The second one would be, is that treatment making a change in the course of the life for the patients? And hopefully, we will have more data to really show that.
And the third would be, is there a mechanism to be able to scale it up in terms of the production that the patients benefit from it?
Because the last thing you want is that the treatment gets approved, but it is not available to most people. And I'm very grateful that the regulatory authorities, including the FDA, take all of these into account. What is very reassuring is that when it comes to the side effects, as I mentioned, these treatments are better tolerated when it comes to their targeted approach for personalized treatment.
Because we're not treating all breast cancer patients the same way. Even in the trials, as you just mentioned, we pick individual personal characteristics of the patient and only enroll them into a trial that fits those characteristics. So it's more customized. And third, because the recognition of radiopharmaceuticals in today's day and age is so much better than it was five, 10 years ago, that there is tremendous investment in scaling the production and availability of radiopharmaceuticals.
It's important because if you buy chemotherapy or immunotherapy, that may have a shelf life of nine months, or a year, or a year and a half. Radiopharmaceuticals only have a shelf life of a few days. So there's a completely different kind of challenge in making sure that radiopharmaceuticals are available across the system, and that includes not just urban areas, but remote areas, as well, which is why at United Theranostics, luckily, we are participating in these cutting-edge trials, but we are strategically placing our centers that are situated where the patients are, so that the patients don't have to travel long distance to benefit from these treatments.
And we make sure that we contract with the radiopharmacies that are able to provide us the delivery of these radiopharmaceuticals, even in the remote areas. For example, one of our centers is in Las Cruces, New Mexico. And that's where a lot of patients, before we open up our centers, had to travel 150 to 200 miles to get to the nearest place where they could get the radiopharmaceutical therapy. Now, we are making it more practical for them to have a more reasonable travel distance for benefiting for these treatments.
Jamie DePolo: That makes sense. Dr. Ghesani, thank you so much for joining us. This has been very informative, and I'm excited to see what comes next for radiopharmaceuticals in breast cancer. So I will definitely keep an eye on this research. Thank you for joining us.
Dr. Munir Ghesani: Thank you, Jamie. I appreciate the invitation, and I enjoyed our conversation.
Thank you for listening to The Breastcancer.org Podcast. Please subscribe on Apple Podcasts, Amazon Music, Spotify, or wherever you listen to podcasts. To share your thoughts about this or any episode, email us at podcast@breastcancer.org, or leave feedback on the podcast episode landing page on our website. And remember, you could find out a lot more information about breast cancer at Breastcancer.org, and you can connect with thousands of people affected by breast cancer by joining our online community.

Munir Ghesani, MD, FACNM, FACR, FACNM, is a nuclear medicine physician and chief medical officer at United Theranostics in Minneapolis, MN, and medical director at United Theranostics in Princeton, NJ.
Your donation goes directly to what you read, hear, and see on Breastcancer.org.